137 related articles for article (PubMed ID: 2158559)
1. A model for compounds active against human rhinovirus-14 based on X-ray crystallography data.
Diana GD; Treasurywala AM; Bailey TR; Oglesby RC; Pevear DC; Dutko FJ
J Med Chem; 1990 May; 33(5):1306-11. PubMed ID: 2158559
[TBL] [Abstract][Full Text] [Related]
2. CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14.
Diana GD; Kowalczyk P; Treasurywala AM; Oglesby RC; Pevear DC; Dutko FJ
J Med Chem; 1992 Mar; 35(6):1002-8. PubMed ID: 1313108
[TBL] [Abstract][Full Text] [Related]
3. Conformationally restricted analogues of disoxaril: a comparison of the activity against human rhinovirus types 14 and 1A.
Mallamo JP; Diana GD; Pevear DC; Dutko FJ; Chapman MS; Kim KH; Minor I; Oliveira M; Rossmann MG
J Med Chem; 1992 Dec; 35(25):4690-5. PubMed ID: 1335081
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.
Diana GD; Oglesby RC; Akullian V; Carabateas PM; Cutcliffe D; Mallamo JP; Otto MJ; McKinlay MA; Maliski EG; Michalec SJ
J Med Chem; 1987 Feb; 30(2):383-8. PubMed ID: 3027340
[TBL] [Abstract][Full Text] [Related]
5. Antipicornavirus activity of tetrazole analogues related to disoxaril.
Diana GD; Cutcliffe D; Volkots DL; Mallamo JP; Bailey TR; Vescio N; Oglesby RC; Nitz TJ; Wetzel J; Giranda V
J Med Chem; 1993 Oct; 36(22):3240-50. PubMed ID: 8230114
[TBL] [Abstract][Full Text] [Related]
6. Enantiomeric effects of homologues of disoxaril on the inhibitory activity against human rhinovirus-14.
Diana GD; Otto MJ; Treasurywala AM; McKinlay MA; Oglesby RC; Maliski EG; Rossmann MG; Smith TJ
J Med Chem; 1988 Mar; 31(3):540-4. PubMed ID: 2831362
[TBL] [Abstract][Full Text] [Related]
7. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.
Fox MP; McKinlay MA; Diana GD; Dutko FJ
Antimicrob Agents Chemother; 1991 Jun; 35(6):1040-7. PubMed ID: 1656851
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14.
Oren DA; Zhang A; Nesvadba H; Rosenwirth B; Arnold E
J Mol Biol; 1996 May; 259(1):120-34. PubMed ID: 8648640
[TBL] [Abstract][Full Text] [Related]
9. Antirhinoviral activity of heterocyclic analogs of Win 54954.
Bailey TR; Diana GD; Kowalczyk PJ; Akullian V; Eissenstat MA; Cutcliffe D; Mallamo JP; Carabateas PM; Pevear DC
J Med Chem; 1992 Nov; 35(24):4628-33. PubMed ID: 1335079
[TBL] [Abstract][Full Text] [Related]
10. Disoxaril-related 3-(diethylamino)-5-phenylisoxazoles.
Mazzei M; Dondero R; Ledda B; Demontis F; Vargiu L
Farmaco; 2000 Feb; 55(2):119-24. PubMed ID: 10782382
[TBL] [Abstract][Full Text] [Related]
11. A novel basis of capsid stabilization by antiviral compounds.
Phelps DK; Post CB
J Mol Biol; 1995 Dec; 254(4):544-51. PubMed ID: 7500332
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antirhinovirus activity of 3-(diethylamino)-5-phenylisoxazole derivatives.
Mazzei M; Garzoglio R; Balbi A; Grandi T; De Montis A; Corrias S; La Colla P
Farmaco; 1996 May; 51(5):351-9. PubMed ID: 8767845
[TBL] [Abstract][Full Text] [Related]
13. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.
Dewindt B; van Eemeren K; Andries K
Antiviral Res; 1994 Sep; 25(1):67-72. PubMed ID: 7811059
[TBL] [Abstract][Full Text] [Related]
14. Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
Hadfield AT; Oliveira MA; Kim KH; Minor I; Kremer MJ; Heinz BA; Shepard D; Pevear DC; Rueckert RR; Rossmann MG
J Mol Biol; 1995 Oct; 253(1):61-73. PubMed ID: 7473717
[TBL] [Abstract][Full Text] [Related]
15. Human rhinovirus capsid dynamics is controlled by canyon flexibility.
Reisdorph N; Thomas JJ; Katpally U; Chase E; Harris K; Siuzdak G; Smith TJ
Virology; 2003 Sep; 314(1):34-44. PubMed ID: 14517058
[TBL] [Abstract][Full Text] [Related]
16. Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication.
Kuz'min VE; Artemenko AG; Muratov EN; Volineckaya IL; Makarov VA; Riabova OB; Wutzler P; Schmidtke M
J Med Chem; 2007 Aug; 50(17):4205-13. PubMed ID: 17665898
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
Dragovich PS; Prins TJ; Zhou R; Webber SE; Marakovits JT; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Ford CE; Burke BJ; Rejto PA; Hendrickson TF; Tuntland T; Brown EL; Meador JW; Ferre RA; Harr JE; Kosa MB; Worland ST
J Med Chem; 1999 Apr; 42(7):1213-24. PubMed ID: 10197965
[TBL] [Abstract][Full Text] [Related]
18. A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program.
Andries K; Dewindt B; Snoeks J; Willebrords R; Stokbroekx R; Lewi PJ
Antiviral Res; 1991 Oct; 16(3):213-25. PubMed ID: 1666824
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of antiviral agents that interact with the capsid of human rhinoviruses.
Badger J; Minor I; Oliveira MA; Smith TJ; Rossmann MG
Proteins; 1989; 6(1):1-19. PubMed ID: 2558377
[TBL] [Abstract][Full Text] [Related]
20. Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site.
Wald J; Pasin M; Richter M; Walther C; Mathai N; Kirchmair J; Makarov VA; Goessweiner-Mohr N; Marlovits TC; Zanella I; Real-Hohn A; Verdaguer N; Blaas D; Schmidtke M
Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19109-19115. PubMed ID: 31462495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
